Recruitment

Recruitment Status
Completed
Estimated Enrollment
1500

Inclusion Criterias

Receiving vancomycin therapy for definitive use
Inpatients of National Taiwan University Hospital
Age above or equal to 20 years old
...
Receiving vancomycin therapy for definitive use
Inpatients of National Taiwan University Hospital
Age above or equal to 20 years old
Positive methicillin-resistant Staphylococcus aureus blood culture
Undergoing therapeutic drug monitoring (had serum vancomycin concentration level)

Exclusion Criterias

With abnormal and undefined serum concentration
Without renal function data (serum creatinine level, creatinine clearance)
Without details of vancomycin dose and frequency
...
With abnormal and undefined serum concentration
Without renal function data (serum creatinine level, creatinine clearance)
Without details of vancomycin dose and frequency
Age below 20 years old
Therapeutic drug monitoring before reaching steady state
Without infection-related clinical outcomes (lab data such as white blood cell count , seg, C reactive protein , body temperature records)
Vancomycin treatment shorter than 72 hours
Receiving renal replacement therapy

Summary

Conditions
Methicillin-resistant Staphylococcus Aureus Septicemia
Type
Observational
Design
  • Observational Model: Cohort
  • Time Perspective: Retrospective

Participation Requirements

Age
Between 20 years and 125 years
Gender
Both males and females

Description

Several studies have shown AUC/MIC to be the better pharmacokinetic-pharmacodynamic parameter for clinical effectiveness of vancomycin. However, the 2009 consensus guideline for vancomycin therapeutic monitoring continued to recommend trough serum concentration monitoring in the clinical setting. In...

Several studies have shown AUC/MIC to be the better pharmacokinetic-pharmacodynamic parameter for clinical effectiveness of vancomycin. However, the 2009 consensus guideline for vancomycin therapeutic monitoring continued to recommend trough serum concentration monitoring in the clinical setting. In 2011, Patel et al showed that highly difference between AUC(72-96h) and Cmin(96h). Different dosing and creatinine clearance may reach the same trough drug level with different AUC. The investigators wonder whether trough drug level can serve as a substitute marker for AUC and as a parameter for vancomycin therapeutic monitoring. In this study, the investigators will calculate AUC/MIC of vancomycin with published formula, analyze its correlation with patient's clinical outcome and compare that with trough drug level.

Inclusion Criterias

Receiving vancomycin therapy for definitive use
Inpatients of National Taiwan University Hospital
Age above or equal to 20 years old
...
Receiving vancomycin therapy for definitive use
Inpatients of National Taiwan University Hospital
Age above or equal to 20 years old
Positive methicillin-resistant Staphylococcus aureus blood culture
Undergoing therapeutic drug monitoring (had serum vancomycin concentration level)

Exclusion Criterias

With abnormal and undefined serum concentration
Without renal function data (serum creatinine level, creatinine clearance)
Without details of vancomycin dose and frequency
...
With abnormal and undefined serum concentration
Without renal function data (serum creatinine level, creatinine clearance)
Without details of vancomycin dose and frequency
Age below 20 years old
Therapeutic drug monitoring before reaching steady state
Without infection-related clinical outcomes (lab data such as white blood cell count , seg, C reactive protein , body temperature records)
Vancomycin treatment shorter than 72 hours
Receiving renal replacement therapy

Locations

Taipei
Taipei

Tracking Information

NCT #
NCT01995760
Collaborators
Not Provided
Investigators
  • Principal Investigator: Li-Jiuan Shen National Taiwan University Hospital
  • Li-Jiuan Shen National Taiwan University Hospital